AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01424644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Description: All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus \[Types 6, 11, 16, 18\] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®.
Study NCT01655628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)
Description: A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
Study NCT01655628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GC chemotherapy (Gemcitabine, Cisplatin)
Description: A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
Study NCT01674582 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI, neuropsychological evaluation, blood sampling
Description: MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years.
Study NCT01179048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Study NCT01179048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Study NCT01832701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coffee
Description: coffee versus placebo
Study NCT01832701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: maltodextrine with caffeine
Study NCT01091090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral
Description: Cognitive behavioral intervention for smoking cessation
Study NCT01091090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual
Study NCT01864330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo®
Description: Eye Drops
Study NCT01864330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyabak®
Description: Eye Drops
Study NCT01864330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrabak®
Description: Eye Drops
Study NCT02486822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
Study NCT02486822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
Study NCT02486822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
Study NCT02486822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
Study NCT02486822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
Study NCT02486822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section
Description: Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
Study NCT04588753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active isolated stretch
Description: Active Isolated Stretch (AIS);~* The shortened hamstring muscle will be isolated.~* The hamstring will be stretched.~* This Stretches will be Repeated eight to 10 times.~* Stretch will be hold for no more than two seconds.~* Exhale on the stretch; inhale on the release. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs
Study NCT04588753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Facilitation Stretch
Description: Participants of this group will receive Post Facilitation Stretch (PFS);~* The shortened hamstring muscle will be placed between a fully stretched and a fully relaxed state.~* The patient will be asked to contract the hamstring using a maximum degree of effort for 5-10 seconds while the therapist will resists thepatients force.~* The patient will be then asked to relax and release the effort, whereas the therapist will apply a rapid stretch to a new barrier and is held for 10 seconds.~* The patient relaxes for approximately 20 seconds and the procedure will be repeated to five times (8) (18).~  2. Other amputees training exercises;~* weight-shifting~* Dynamic balancing activities~* Stool stepping~* Braiding~* Gait exercises~* Climbing/descending the stairs
Study NCT02298322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting System
Study NCT01391793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 3 days
Study NCT01391793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.15 mg/kg/dose twice daily for 3 days
Study NCT02958111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
Study NCT00002994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin 2
Description: low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
Study NCT00002994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhuMAb
Description: 90 min IV infusion day 7 of each cycle
Study NCT01690494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT
Description: Couple-based behavioral HIV/STI preventive intervention
Study NCT01690494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
Study NCT01690494 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
Study NCT00847678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efungumab (Mycograb)
Study NCT00847678 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00847678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Study NCT00847678 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Amphotericin B
Study NCT00847678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 flucytosine
Study NCT00847678 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 5 flucytosine
Study NCT04000217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Exposure Therapy
Description: In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
Study NCT04000217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal Exposure Therapy
Description: Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
Study NCT04305145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infusion
Study NCT04305145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Infusion
Study NCT04305145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Orally
Study NCT00055315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systems Training for Emotional Predictability and Problem Solving (STEPPS)
Description: STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
Study NCT00055315 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual (TAU)
Study NCT00113789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PI Discretion
Description: PI Discretion
Study NCT00113789 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PI Discretion
Description: PI Discretion
Study NCT00757874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus cream
Description: 0.5 g per day at bed time for 3 months or less.
Study NCT00757874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol cream
Description: 0.5 gram each day at bed time during 3 months or less.
Study NCT02293083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trigger point injection
Study NCT02686333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
Study NCT01189123 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose influenza vaccine Sanofi-Pasteur
Description: High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
Study NCT01189123 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fluzone by sanofi pasteur
Description: standard dose fluzone
Study NCT03576846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and Spinal manipulative therapy
Description: Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
Study NCT03576846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
Study NCT04450043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Run-In Sessions 1-5
Description: Session 1 explores patient goals and wishes for life after cancer treatment with a study interventionist. Sessions 2-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
Study NCT04450043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RCT Transitions Program Sessions 1-5
Description: Sessions 1-5 focuses on learning and practicing skills to enhance post-treatment quality of life.
Study NCT04450043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RCT Control Session
Description: Participants will receive a 1-session intervention, focused on reviewing goal progress for post-treatment quality of life, providing encouragement and support, identifying any current concerns, and providing tailored recommendations and resources.
Study NCT02227251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 60 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
Study NCT02227251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 40 mg (BIW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
Study NCT02227251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 60 mg (BIW) and 60 mg (QW); Dosage form: film-coated (20 mg each) immediate release tablets; Route of administration: Oral
Study NCT03204526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Study NCT04366232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra alone (stages 2b/3)
Description: Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
Study NCT04366232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra and Ruxolitinib (overcome stage 3)
Description: Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
Study NCT04366232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Routine clinical care for Covid-19
Study NCT03729310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Propel 'implant'
Description: The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
Study NCT03729310 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone
Description: Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
Study NCT03729310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopore
Description: This packing' is a sponge-like material which dissolves while releasing triamcinolone.
Study NCT03727568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Description: In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies
Study NCT00893256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
Study NCT00893256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
Study NCT00893256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
Study NCT00893256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: once daily
Study NCT00719316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300mg per day for 6 weeks
Study NCT02869646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure: Acupuncture
Description: Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
Study NCT02869646 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Procedure: Sham acupuncture
Description: Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
Study NCT03998865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provisional abutment material
Description: The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
Study NCT03998865 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provisional abutment material
Description: The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
Study NCT01295853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: t3 sympathicotomy
Description: The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
Study NCT01295853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: t4 symapthicotomy
Description: The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
Study NCT02166138 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Abilative Laser treatment
Description: Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
Study NCT04341740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: bone marrow aspiration
Study NCT00946803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Cognitive-Behavioral Intervention
Description: Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
Study NCT02539485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: heating precondition
Description: The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
Study NCT03659656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle coaching
Description: Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
Study NCT03659656 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit usage
Description: The participants will have a Fitbit to use for 3 months.
Study NCT03659656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit usage
Description: The participants will have a Fitbit to use for 3 months.
Study NCT04408404 — intervention group
Intervention type: PROCEDURE
Intervention: Acute aortic dissection
Description: Acute aortic dissection treatment include Bentall procedure, Tyrone David procedure, Yacoub procedure or ascendant aortic replacement with or without aortic valve replacement, ascendant aortic root remodelling (all are standard of care procedures)